Last reviewed · How we verify
AD07010
AD07010 is a small molecule that targets the PI3K/AKT/mTOR pathway.
AD07010 is a small molecule that targets the PI3K/AKT/mTOR pathway. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | AD07010 |
|---|---|
| Also known as | LTh(αK), Escherichia coli heat-labile enterotoxin |
| Sponsor | Advagene Biopharma Co. Ltd. |
| Drug class | PI3K/mTOR inhibitor |
| Target | PI3K/AKT/mTOR pathway |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AD07010 works by inhibiting the PI3K/AKT/mTOR pathway, which is involved in cell growth and survival. This inhibition leads to a decrease in tumor growth and proliferation. Additionally, AD07010 has been shown to induce apoptosis in cancer cells.
Approved indications
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AD07010 CI brief — competitive landscape report
- AD07010 updates RSS · CI watch RSS
- Advagene Biopharma Co. Ltd. portfolio CI